Peter R Paradiso

US Patent:

7118757, Oct 10, 2006

Filed:

Feb 15, 1994

Appl. No.:

08/204808

Inventors:

Peter R. Paradiso - Pittsford NY, US
Jan T. Poolman - Broek in Waterland, NL
Peter Hoogerhout - Bilthoven, NL
Emmanuel J. H. J. Wiertz - Utrecht, NL
Peter van der Ley - Utrecht, NL
John Edward Heckels - Romsey, GB
Ian Nicholas Clarke - Southampton, GB

Assignee:

Wyeth Holdings Corporation - Madison NJ
De Staat der Nederlanden Vertegenwoordigd Door de Minister Van Welzijn, Volksgezondheid en Cultuur - Bilthoven

International Classification:

A61K 39/095
A61K 39/02
A61K 39/385
A61K 39/38
C07K 1/00

US Classification:

4242501, 4242341, 4241901, 4241841, 42419711, 4241941, 530350, 530300, 530825, 530807, 530806

Abstract:

Outer-membrane vesicles, Class 1 outer membrane proteins of , fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease.

US Patent:

7238345, Jul 3, 2007

Filed:

Jun 5, 1995

Appl. No.:

08/461651

Inventors:

Peter R. Paradiso - Pittsford NY, US
Jan T. Poolman - Broek in Waterland, NL
Peter Hoogerhout - Bilthoven, NL
Emmanuel J. H. J. Wiertz - Utrecht, NL
Peter van der Ley - Utrecht, NL
John Edward Heckels - Romsey, GB
Ian Nicholas Clarke - Southampton, GB

Assignee:

Wyeth Holdings Corporation - Madison NJ

International Classification:

A01N 63/00
A61K 39/02
A61K 39/095
C07H 21/04
C12N 15/74
C12N 15/09
C12P 21/04

US Classification:

424 932, 4242001, 4242341, 424 934, 4241921, 4242501, 424 9348, 536 237, 4352301, 435 711, 435 693, 435 697

Abstract:

Outer-membrane vesicles, Class 1 outer membrane proteins of fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease.

US Patent:

56914490, Nov 25, 1997

Filed:

May 25, 1995

Appl. No.:

8/450070

Inventors:

Peter R. Paradiso - Pittsford NY
Stephen W. Hildreth - Rochester NY
Branda T. Hu - Pittsford NY
Rasappa Arumugham - West Henrietta NY
Edward E. Walsh - Pittsford NY

Assignee:

Praxis Biologics, Inc. - Rochester NY

International Classification:

C07K 100
C07K 1400
C07K 1700
A61K 39155

US Classification:

530350

Abstract:

Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion protein or a neutralizing epitope of the G protein.

US Patent:

56398530, Jun 17, 1997

Filed:

Sep 20, 1989

Appl. No.:

7/409915

Inventors:

Peter R. Paradiso - Pittsford NY
Stephen W. Hildreth - Rochester NY
Branda T. Hu - Pittsford NY
Rasappa Arumugham - West Henrietta NY
Edward E. Walsh - Pittsford NY

Assignee:

Praxis Biologics, Inc. - Rochester NY

International Classification:

C07K 100
C07K 500
A61K 3800
A61K 39155

US Classification:

530324

Abstract:

Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion protein or a neutralizing epitope of the G protein.

US Patent:

52232549, Jun 29, 1993

Filed:

Sep 20, 1988

Appl. No.:

7/247017

Inventors:

Peter R. Paradiso - Pittsford NY
Stephen W. Hildreth - Rochester NY
Branda T. Hu - Pittsford NY
Rasappa Arumugham - West Henrietta NY

Assignee:

Praxis Biologics, Inc. - Rochester NY

International Classification:

A61K 39155

US Classification:

424 89

Abstract:

Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion protein or a neutralizing epitope of the G protein.

US Patent:

20210283247, Sep 16, 2021

Filed:

May 24, 2021

Appl. No.:

17/328657

Inventors:

- New York NY, US
George Rainer Siber - New York NY, US
Peter R. Paradiso - Radnor PA, US

International Classification:

A61K 39/385
A61K 47/64
A61K 39/09
A61K 39/39

Abstract:

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.

US Patent:

20200179508, Jun 11, 2020

Filed:

Feb 19, 2020

Appl. No.:

16/794315

Inventors:

- New York NY, US
George Rainer Siber - New York NY, US
Peter R. Paradiso - Radnor PA, US

International Classification:

A61K 39/385
A61K 47/64
A61K 39/09
A61K 39/39

Abstract:

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.

US Patent:

20190388537, Dec 26, 2019

Filed:

Aug 1, 2019

Appl. No.:

16/528680

Inventors:

- New York NY, US
George Rainer Siber - New York NY, US
Peter R. Paradiso - Radnor PA, US

International Classification:

A61K 39/385
A61K 47/64
A61K 39/09
A61K 39/39

Abstract:

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.